Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor.
Introduction: Evidence suggests that many cancer chemotherapy patients who are candidates for colony-stimulating factor (CSF) prophylaxis do not receive it or receive it inconsistent with guidelines, and that such patients have a higher risk of febrile neutropenia hospitalization (FNH). Little is kn...
| Publicado en: | Supportive Care in Cancer Vol. 25; no. 2; pp. 439 - 448 |
|---|---|
| Autores principales: | , , , , , , , , |
| Formato: | research Journal Article |
| Publicado: |
Springer Nature
Feb2017
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=120437030&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 120437030 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 09414355 O1J jtl: Supportive Care in Cancer issn: 09414355 maglogo: N pubinfo: dt: Feb2017 vid: 25 iid: 2 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 120437030 120437030 144028815 NLM27734153 120437030 10.1007/s00520-016-3421-x NLM27734153 120437030 ppf: 439 ppct: 9 formats: fmt: @attributes: type: P tig: atl: Burden of Chemotherapy-Induced Febrile Neutropenia Hospitalizations in US Clinical Practice, by Use and Patterns of Prophylaxis with Colony-Stimulating Factor. aug: au: Weycker, Derek Li, Xiaoyan Tzivelekis, Spiros Atwood, Mark Garcia, Jacob Li, Yanli Reiner, Maureen Lyman, Gary Lyman, Gary H affil: Policy Analysis Inc. (PAI) , Four Davis Court Brookline 02445 USA sug: subj: Colony-Stimulating Factors Administration and Dosage Granulocyte Colony-Stimulating Factor Administration and Dosage Risk Factors Middle Age Female Retrospective Design Breast Neoplasms Drug Therapy Aged Hospitalization Statistics and Numerical Data Lymphoma, Non-Hodgkin's Drug Therapy Antineoplastic Agents, Combined Adverse Effects Neutropenia Chemically Induced Prospective Studies Human Middle Aged: 45-64 years Aged: 65+ years Female ab: Introduction: Evidence suggests that many cancer chemotherapy patients who are candidates for colony-stimulating factor (CSF) prophylaxis do not receive it or receive it inconsistent with guidelines, and that such patients have a higher risk of febrile neutropenia hospitalization (FNH). Little is known about the number and consequences of FNH by use/patterns of CSF prophylaxis in US clinical practice.Methods: A retrospective cohort design and private healthcare claims data were employed. Study population comprised adults who received a chemotherapy course with a high-risk regimen, or an intermediate-risk regimen (if ≥1 FN risk factor present), for non-metastatic breast cancer or non-Hodgkin's lymphoma (NHL); each chemotherapy cycle within the course and each FNH episode within the cycles were identified. Consequences included mortality, inpatient days, and costs (US$2013) during FNH. Use (yes/no) and patterns (agent, administration day/duration) of CSF prophylaxis were evaluated within cycles in which FNH episodes occurred.Results: Among all FNH episodes (n=6,355; 109 episodes per 1,000 patients), 41.3% (95% CI: 40.1-42.5) occurred among patients who did not receive CSF prophylaxis in that cycle, and 8.8% (8.1-9.5) occurred among those who received CSF prophylaxis on the same day as chemotherapy. Among FNH episodes occurring in patients who received daily CSF agents (2% of CSF use), 56.1% (44.1-68.0) received prophylaxis <7 days during the cycle. Results for FNH consequences were comparable.Conclusions: In this retrospective evaluation, one-half of FNH episodes, outcomes, and costs among cancer chemotherapy patients who were candidates for CSF prophylaxis occurred in those who either did not receive it or received it inconsistent with guidelines. pubtype: Academic Journal doctype: research Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|